Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [ <sup>68</sup> Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer
Ga]Ga-OncoACP3-DOTA demonstrated favorable pharmacokinetics with increasing tumor uptake and tumor-to-background ratios at later time points, suggesting potential benefits for delayed imaging, especially with high-sensitive PET systems or radiolabeling with isotopes with longer half-lives. The dosimetry profile was favorable, with a lower effective dose compared with many prostate-specific membrane antigen-targeted radiopharmaceuticals and negligible salivary gland uptake, potentially reducing side effects during radiopharmaceutical therapy. Future studies are warranted to evaluate its clinical value.
Authors
- Florian Büther
- Samuele Cazzamalli (ORCID: https://orcid.org/0000-0003-0510-5664)
- Katrin Schlack (ORCID: https://orcid.org/0000-0001-5843-140X)
- Tony Georgiev (ORCID: https://orcid.org/0000-0001-8888-7096)
- Philipp Backhaus (ORCID: https://orcid.org/0000-0003-4164-4104)
- K.-F. Seifert (ORCID: https://orcid.org/0000-0002-9109-9004)
- Andrea Ciamarone (ORCID: https://orcid.org/0009-0001-7841-1964)
- Sebastian Oehler (ORCID: https://orcid.org/0000-0002-5394-2857)
- Hans‐Jörg Breyholz (ORCID: https://orcid.org/0000-0001-6060-6360)
- Andres Jan Schrader (ORCID: https://orcid.org/0000-0002-9435-7347)
- Emanuele Puca (ORCID: https://orcid.org/0000-0002-2869-3203)
- Felicitas Landau
- David Ventura
- Martin Rust
- J Mock
- D Neri
- Julia Brosch-Lenz
- P Schindler
- Kambiz Rahbar
- Michael Schäfers
- Martin Bögemann
Institutions
- University of Münster (DE)
- University Hospital Münster (DE)
- Philogen (Italy) (IT)
- Philochem (Switzerland) (CH)
- École Polytechnique Fédérale de Lausanne (CH)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2026-04-30
- DOI
- https://doi.org/10.2967/jnumed.125.271933
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00